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Open access under Reply to: ‘‘To target or not to target viral antigens
in HBV related HCC?’’To the Editor:
We welcome a discussion about the therapeutic potential of
HBV-speciﬁc TCR redirected (HBV-TCR) T cells in HBV-related
HCC offered by Buschow et al., who express strong reservations
about the conclusions of our recent work [1] and about the use
of HBV antigen as a target of HCC immunotherapy.
First, Buschow et al. challenged our idea that HBV antigen can
be used as a target for HCC immunotherapy, suggesting that in our
HBV-TCR T cell treated patient we ‘‘lack evidence to conclude that
T cells really acted on tumor cells’’. They are instead proposing
that the drop of HBsAg observed in the patient could be explained
by the T cells targeting ‘‘some level of undetectable HBV infection
of the transplanted liver’’ and not the HCC metastases.
In the liver-transplanted patient with extrahepatic HCC
metastases described in our report (see Supplementary Material
of our paper for the detailed clinical history) [1], liver biopsies
were obtained from the transplanted liver and from the extrahep-
atic HCC metastases. HBsAg was found only in HCC metastases
and not in the liver.
Furthermore, despite not being on anti-viral therapy, the
patient sera was HBsAg positive but consistently HBV-DNA
negative (a test performed monthly for the ﬁrst 3 years after
transplantation and every 3 months thereafter). HBV-DNA was
also not found in the biopsy of the transplanted liver, while a trun-
cated HBV-DNA coding only for HBsAg was detected in the biopsy
material of the HCC metastasis. We sequenced this integrated
section of HBV-DNA and demonstrated that it was coding for a
non-mutated sequence of the HBs183-91 region that is recog-
nized by our HBs183-91-directed TCR. We further characterized
the extrahepatic HCC metastasis by staining them with a T cell
receptor-like antibody speciﬁc for HBs183-91/HLA-A2 [2],
demonstrating that HCC cells of this patient presented these
speciﬁc HBV-peptide/HLA-class I complexes on their surface.
Thus, we have provided extensive experimental evidence showing
that HCC metastasis can process and present HBsAg in a form
recognizable by our adoptively transferred HBV-TCR T cells. In
contrast we failed to ﬁnd any evidence of the presence of HBV
and/or HBsAg expression in the transplanted liver of this patient.
Based on these results we have difﬁculty understanding how
Buschow could hypothesize that the HBsAg drop and the HBV-
TCR T cell expansion observed after adoptive transfer derived
from T cell recognition of HBV-infected hepatocytes (that we can-
not detect) and not, simply, from the recognition of extrahepatic
HBsAg-expressing HCC cells.
Buschow et al. may say that only ‘‘seeing is believing’’ and we
have to admit that we do not have a direct in vivo visualization of
adoptively transferred T cells interacting with HCC cells in the
patient. Nevertheless, we prefer to base our interpretation on
the experimental evidences and not on speculation.
Buschow et al. then criticized the use of HBV antigen as anHCC-
tumor antigen for immune intervention, providing arguments of
limited quantitative and temporal HBV antigen expression in
HCC cells and stressing the supposed ‘‘rarity’’ of our reported case.
They argued that ‘‘For a long lasting therapeutic effect, HBV
antigens need to be stably expressed by tumor cells and presented
by MHC-I molecules’’ and point out that we did not test in our
report if the tumor evolved to an HBsAg negative status under
immune attack. To support the limited HBV antigen expression
in HCC they quote a study of Faria et al. [3] that reported a reduced
expression ofHBsAg in tumorsdespite thepresence ofHBV-DNA in
most HCC recurrences.
The question of stability of HBsAg expression under
immunotherapy is puzzling and, we have argued in our
report that, HBV-TCR T cells could not only lyse but also
modulate HBsAg expression. Nevertheless, in previous
experiments in animal models, adoptive transfer of HBV-
TCR T cells did not suppress HBsAg production but resulted
in lysis of HCC cells [4,5].Journal of Hepatology 2015 vol. 62 j 1438–1454
CC BY-NC-ND license.
Here, we would like to focus the discussion on the setting of
HCC relapses occurring in liver-transplanted patients. Buschow
et al. state that since HBV re-infection of the transplanted liver
can supposedly occur frequently, the risk of liver damage due
to the recognition of HBV infected hepatocytes by the adoptively
transfer HBV-TCR T cell remains ‘‘unacceptably high’’. However,
what Buschow et al. do not consider is the possibility to use
therapeutic TCR that recognize HBV antigens presented by HLA
alleles expressed in the metastatic HCC lesions but not in an
HLA-mismatched liver transplant. This level of personalized con-
struction of T cells results in the adoptive transfer of HBV-speciﬁc
T cells that cannot recognize HBV infected hepatocytes of the
transplanted liver. This is why we reject Buschow’s statement
that TCR-HBV based therapy would subject liver transplanted
patients to a ‘‘considerable risk of collateral damage’’. Certainly,
results obtained from a single case should be taken with caution
and we agree that immunotherapy carries inherent risks [9].
However, the targeting of normal HBV infected hepatocytes in
liver transplanted patients can be theoretically eliminated after
a careful characterization of the patients’ pathology, HLA-proﬁle
and the subsequent precise and selective engineering of HBV-
TCR T cells.
In conclusion, despite the criticisms expressed by Buschow
et al., we are convinced that HBV antigen can be a target of
HCC immunotherapy. Our data [1], combined with the
characterization of the frequency of HBV-RNA [8] and HBV-DNA
integration in early [10] and late-onset [3,6] HCC, support this
possibility. Certainly we are far from concluding that HBV-TCR
T cells constitute ‘‘the cure’’ for such devastating diseases, but
we derived a ‘‘glimpse of hope’’ from our ﬁrst attempt to target
HBV antigen in HCC using engineered T cells.
Ironically, after having argued about the un-suitability of HBV
as an HCC target, Buschow proposes to target ‘‘HBV mutated pro-
tein’’ in HCC, an option that is in agreement with our conclusion
to evaluate HBV antigen as a target for HCC. However, it is not
clear how HBV mutated sequences could be selectively expressed
in HCC and not in normal HBV infected hepatocytes and why, dif-
ferently from non-mutated sequences, these should be stably
expressed. Nevertheless, we welcome any discussions that boost
research in this area and help design new therapies that can pro-
vide hope to the patients affected by HCC.
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However, stable HBV antigen expression and MHC-class I
presentation (before therapy) was not only detected in the HCC
cells of our treated patient but also on other natural HCC cell lines
with HBV-DNA integration [4].
Thus, at themoment, the experimental evidence shows that, at
least at the time of therapy, HBV antigen was stably expressed in
HCC cells, while there was no experimental evidence of the oppo-
site. Indeed Buschow’s argument that ‘‘HBsAg expression’’ was not
detected inmostHCC cellswithHBV-DNA integration or thatHBV-
DNA integration leads to disruption of the viral proteins or expres-
sion of host-viral chimeric protein is misleading since it does not
take into consideration the difference between viral antigen recog-
nition by T cell receptors or by antibodies. The fact that antibodies
would fail to detect HBsAg in cells with HBV-DNA integration (as
quotedbyFaria et al. [3]) shows that thewholeHBsAg,with the cor-
rect conformation speciﬁc for the used antibody,was not produced
in these HCC cells. However, negative detection with an antibody
cannot exclude that the HBsAg with a different conformation or
only a selected section of the antigen are expressed. T cells recog-
nize short fragments of viral proteins presented by HLA-class I
molecules and such fragments can perfectly result from the pro-
cessing of truncated proteins. This is why, in contrast to what
Buschow argued, we consider the high incidence of HBV-DNA
integration [3,6] (truncatedHBV-DNAor hybridizedwith host pro-
tein [7]) inHBV relatedHCCnot as a drawbackbut as a great oppor-
tunity for TCR-mediated immunotherapy. Certainly, as we
discussed in a recent commentary (Bertoletti et al.,
Oncoimmunology 2015 in press), more work needs to be done to
understand the difference betweenT cell recognition of HCC trans-
formedhepatocytes or of HBV infected hepatocytes and tomap the
landscape of HBV epitopes expressed in HCC with HBV-DNA
integration. Also Buschow’s suggestion that methylation or muta-
tion of the integratedHBVgeneswill result in reduced viral protein
expression is, in our opinion, weak. T cells can be activated by very
few viral peptide/HLA complexes present on the target cell surface
and our virus-speciﬁc TCR are of high avidity, being able to recog-
nize target pulsed with femtomolar concentrations of peptide
[2,4].More importantly, recentwork characterized thewhole tran-
scriptome of different viral related tumors and demonstrated the
presence of HBV related mRNA in more than 30% of analyzed
HCC [8]. If we consider that in this analysis, liver tumors were
not necessarily HBV-related, it appears difﬁcult to agree with
Buschow’s assertion that expression ofHBVproducts inHCC repre-
sents an exceptional event.
Last, Buschow et al. argued that our therapy is characterized by
high and unacceptable risk for the patient. Patient safety is our
primary concern and this is why we treated our patient only after
repetitive testing showing that HBV was undetectable in the
transplanted liver. We agree that such therapy could carry risk
to non-liver transplanted HCC patients, where HBV-speciﬁc TCR
can also target non-malignant HBV infected hepatocytes.
Nevertheless, immunotherapeutic approaches to boost T cell
responses in patients with ongoing HBV replication in the liver
are being actively considered by a number of groups; discussion
of this is beyond the scope of this response. However, we are
developing a strategy involving mRNA TCR electroporation to
shorten the length of TCR-expression on T cells with the goal of
reducing the risk of liver damage in HCC patients who have not
received a liver transplant [5]. A further alternative would be to
include a suicide gene mechanism to allow transduced T cells to
be eliminated in case of unwanted effects in vivo.Journal of Hepatology 2015 vol. 62 j 1438–1454 1451
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Poor contrast enhanced ultrasonography! There is no limit to its
decline in the diagnosis of hepatocellular carcinoma on cirrhosis!
To the Editor
We have read with great interest the article by Forner and co-
workers, who described the use of contrast-enhanced ultrasound
(CEUS) to deﬁne the priority for diagnostic work-up of hep-
atocellular carcinoma (HCC) nodules <2 cm arising in cirrhotic
livers during ultrasound (US) surveillance [1].
Nevertheless we would like to make some criticism
In their prospective study carried out from 2003 to 2011, the
authors state that ﬁne needle biopsy (FNB) result was considered
the gold standard for diagnosis of HCC, but that after 2007, they
considered only enhanced MRI result as gold standard, as priory
validated. Our question to the authors is why did they not con-
tinue to perform FNB to diagnose HCC nodules? It seems to us
methodologically incorrect to change the diagnostic method dur-
ing the study. Maybe MRI has 100% speciﬁcity in diagnosing
HCC? As far as we know, in a recent meta-analysis comparing
CEUS and enhanced MRI for diagnosis of HCC [2], including only
patients diagnosed with percutaneous biopsy [3,4], CEUS showed
a statistically better speciﬁcity than MRI in the pair-wise compar-
isons (0.86 vs. 0.78; p = 0.014), and a statistically better sensitiv-
ity than computed tomography [(CT) 0.88 vs. 0.78; p = 0.030] [2].
In addition, in a recent work, the speciﬁcity of CEUS plus CT and/
or MRI was signiﬁcantly higher than the speciﬁcity of CT and/or
MRI, CEUS, or intraoperative ultrasound [(IOUS) p = 0.004,
p = 0.002, and p = 0.002, respectively]. The diagnostic accuracy
of CEUS plus CT/MRI was higher than that of CT/MRI (p = 0.001)
[5].
Furthermore, in a speciﬁc section, the authors state that FNB
was performed using a 20 G spinal needle, and state that, when
‘‘technically feasible because of location and accessibility, a core
biopsywas performedusing a 18Gneedle biopsy’’. Fromhistology,
there were 3 intrahepatic cholangiocarcinomas (ICCs) and 35
regenerating nodules or dysplastic nodules and 1 neuroendocrine
tumor. It is evident that diagnosis of ICC and dysplastic nodules
can be made only using histology. Another question arises: were
all ICCs anddysplastic nodules andmetastasis of endocrine tumors
located in a ‘‘feasible and accessible location’’ in the liver? It seems
improbable to us.Moreover, it is probably incorrect to use the term
FNB when two different needles are used for performing biopsies,
since the 18 G needle is not deﬁnable as ‘‘ﬁne’’, as it is >1 mm.
In addition, 3% of cases (5 cases) of US detected nodules were
not evaluable with CEUS examination. Four out of 5 of them were
HCC. This is quite interesting, and it would be useful to know if all
nodules were located in a deep position, since they had been nor-
mally detected with conventional US. It would be also interesting
to know if any MRI resulted unfeasible in the study.
Finally, in the results section, authors reported that 10/18
(55.6%) CEUS un-enhanced patients with ﬁnal diagnosis of HCC,
experienced tumor recurrence after treatment (4 resections and
14 ablations), ‘‘conﬁrming their overt malignant proﬁle’’: how
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